Harrison Farber, MD
Pulmonary Disease · Boston, MANPI 1396721841
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Bayer at 26.1% of the total. Reporting peaked in 2023 at $51,066 and has fallen 61.9% since, to $19,466 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 527 payments — averaging $360.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$50K
- Actelion Pharmaceuticals US, Inc.$46K
- United Therapeutics Corporation$44K
- Merck$20K
- Janssen Scientific Affairs, LLC$9K
- Globus Medical$6K
- plus $16K from 31 others
Across 75 payments — averaging $31,922 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.2M
- Janssen Research & Development, LLC$97K
- Actelion Pharmaceuticals, Ltd$29K
- United Therapeutics Corporation$25K
- Insmed, Inc.$1K
- Gilead$698
What the payments were for
- Consulting fees$109,83758%
- Speaking & faculty fees$30,63616%
- Travel & lodging$26,89914%
- Food & beverage$22,70812%
- Education$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 53 | $49,690 |
| Actelion Pharmaceuticals US, Inc. | 167 | $46,065 |
| United Therapeutics Corporation | 72 | $44,224 |
| Merck | 35 | $20,109 |
| Janssen Scientific Affairs, LLC | 1 | $8,775 |
| Globus Medical(2 entities) | 47 | $5,597 |
| Acceleron Pharma, Inc. | 1 | $3,900 |
| E.r. Squibb & Sons, L.L.C. | 6 | $3,261 |
| Alphatec Spine, Inc | 15 | $2,580 |
| Inari Medical, Inc. | 5 | $1,191 |
| Medtronic | 10 | $932 |
| Boehringer Ingelheim | 15 | $580 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $340 |
| AstraZeneca | 16 | $292 |
| Sanofi | 4 | $270 |
| ZOLL Medical Corporation | 1 | $265 |
| Amgen | 10 | $232 |
| Angiodynamics, Inc. | 2 | $231 |
| Sandoz | 5 | $186 |
| Pfizer | 7 | $182 |
| Daiichi Sankyo Inc. | 7 | $175 |
| Stryker | 2 | $167 |
| Abiomed | 4 | $139 |
| Johnson & Johnson | 5 | $135 |
| Carlsmed, Inc. | 1 | $122 |
| Cardiva Medical, Inc. | 4 | $94 |
| Alnylam Pharmaceuticals Inc. | 3 | $69 |
| Chiesi USA, Inc. | 5 | $69 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $68 |
| Edwards Lifesciences | 1 | $67 |
| Esperion Therapeutics, Inc. | 1 | $55 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Novo Nordisk | 2 | $39 |
| Abbott | 1 | $27 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Acacia Pharma Inc | 1 | $21 |
| Carl Zeiss Meditec, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$49,158
- OPSUMIT$28,647
- ORENITRAM$22,721
- TYVASO$20,233
- REMODULIN$18,267
- UPTRAVI$15,828
- NONE$10,189
- WINREVAIR$1,509
- Other - Miscellaneous$1,285
- BOSENTAN$1,119
- Excelsius - GPS$744
- FlowTriever$714
- ClotTriever$714
- ELSA$675
- TLIF$582
- XLIF$543
- Excelsius3D Imaging System$410
- Invictus MIS$381
- FLOWTRIEVER CATHETER, S$378
- CT THROMBECTOMY SYSTEM KIT$378
How this compares
$190,237 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 115 | $2,724,443 |
| AdempasRiociguat | 130 | $1,722,403 |
| Tyvaso DpiTreprostinil | 72 | $1,712,162 |
| OpsumitMacitentan | 128 | $1,619,453 |
| WinrevairSotatercept-Csrk | 68 | $1,111,556 |
| Ambrisentan | 322 | $1,044,161 |
| OpsynviMacitentan/Tadalafil | 68 | $873,481 |
| Orenitram ErTreprostinil Diolamine | 39 | $671,700 |
| OfevNintedanib Esylate | 23 | $286,852 |
| Tadalafil | 328 | $177,899 |
| AdcircaTadalafil | 35 | $146,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $50,364 |
| AlyqTadalafil | 47 | $28,530 |
| EliquisApixaban | 37 | $23,324 |
| Sildenafil Citrate | 73 | $11,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi | $46,065 | $5,217,376311 claims |
| BayerAdempas | $49,690 | $1,722,403130 claims |
| MerckWinrevair | $20,109 | $1,111,55668 claims |
| Boehringer IngelheimOfev | $580 | $286,85223 claims |
| United Therapeutics CorporationAdcirca | $44,224 | $146,70935 claims |
| PfizerEliquis | $182 | $23,32437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.